Skip to main content
OpenTrials
Completed

NCT Number: NCT04896034

Efficacy of the Photobiomodulation on the Pelvi-perineal Pain in Immediate Post-partum Situation

Photobiomodulation (PBM), evaluated in this study, will be delivered by a CE marked class IIa medical device (MILTA technology), composed of a panel that gathers 18 emitters. This is an innovative, alternative, soft technology, based on a cross action of LED light emission, a low intensity nanopulsed laser and a magnetic tunnel. The sessions last 10 minutes each, in total in the study two sessions will be delivered.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Clinique la Chataigneraie

Beaumont, 63110, France

About this study

In a woman's life, maternity is an important stage that is not without consequences, not only in daily life but also in future life. Perineal pain syndrome is a problem frequently encountered in the postpartum period and the review of the literature shows that 95 to 100% of women who have given birth by the vaginal way and who present perineal lesions, suffer from perineal pain at 24 hours of the delivery and approximately 60% of them remain painful at 7 days of the delivery. This incidence can decrease to 42% and 11% respectively in the absence of perineal lesions.

Pain in the postpartum period can not only limit a woman's mobility and affect her quality of life, but can also interfere with the care of her child and thus with the establishment of a good mother-child relationship, and thus prevent her from fulfilling her new role as a mother. Finally, acute pain that is not treated can become chronic and affect long-term physical and psychological health.

Pain management in the immediate postpartum period currently involves the use of level 1 analgesics (paracetamol, NSAIDs), the effectiveness of which is uncertain, and level 2 analgesics (weak morphine derivatives, Acupan, Tramadol), which are more effective for pain, but are sometimes badly tolerated or contraindicated in the case of breastfeeding. Recently, several publications tend to show that alternative solutions would allow a more satisfactory approach to the management of painful patients.

In this study, the investigators propose to evaluate the benefit of an innovative analgesic treatment in the immediate postpartum period using photobiomodulation (PBM) by evaluating pain using a Visual Analog Scale. PBM, discovered in the 1950s, uses the properties of light. The PBM corresponds to all the non-thermal and non-cytotoxic biological effects caused by the exposure of tissues to light sources in the visible and near-infrared range. More precisely, certain wavelengths of the light spectrum (red-infrared) lead to a cascade of biological effects within the cell: reduction of pain, regulation of inflammation and acceleration of the healing process.

The objective of this study is to analyze the possibility of replacing chemical medication by a non-invasive, painless technology in patients who have just given birth. This technology is already used for anti-inflammatory and analgesic actions in indications such as stomatology, rheumatology, post-operation and traumatology. This is part of the field of NMIs (non-medicinal interventions).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Woman aged 18 years or older
  • Primi or multiparous patient
  • Natural childbirth, regardless of the method of extraction (spontaneous, vacuum, forceps), and damage to the perineum (simple tear, episiotomy, obstetric anal sphincter injury)
  • Patients affiliated to a health insurance plan
  • Agreeing to participate in the study and having signed an informed consent

Exclusion criteria

  • Immediate complications related to the childbirth and requiring management in the continuing care unit (delivery haemorrhage, eclampsia, etc.)
  • Severe neonatal complications requiring reanimation.
  • Patient with a cardiac pacemaker
  • Presence of a disease and/or taking photo-sensitising treatment
  • Patient under legal protection

Treatment and study plan

MILTA Device

Device

Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.

" control 1 " fake MILTA device

Device

Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.

Primary outcomes

  1. Evaluation of the effectiveness of photobiomodulation (PBM) on pain in immediate postpartum patients

    Time frame: 30 minutes after first PBM session for the experimental and control 1 groups

    Evaluated the superiority of the experimental group (MILTA device) to control 1 (fake device) using a Visual Analog Scale (VAS) collected before and after pain management (1st session of PBM)

  2. Evaluation of the effectiveness of photobiomodulation on pain in immediate postpartum patients

    Time frame: 30 minutes after first PBM session for the experimental group or 30 minutes after analgesic treatment for the group control 2

    Evaluated the non-inferiority with of the experimental group (MILTA device) to control 2 (standard of care) using a Visual Analog Scale (VAS) collected before and after pain management

Secondary outcomes

  1. Evaluation of the effectiveness of photobiomodulation on pain after the second PBM session

    Time frame: 30 minutes after second PBM session for the experimental and control 1 groups

    Evaluated the superiority of the experimental group (MILTA device) to control 1 (fake device) using a Visual Analog Scale (VAS) collected before and after pain management (2nd session of PBM)

  2. Characterisation of pain

    Time frame: 30 minutes after first PBM session for the experimental and control 1 groups and 30 minutes after analgesic treatment for the group control 2

    Pain will be characterised using the shortened QDSA questionnaire. The control groups will be compared with the MILTA device.

  3. Characterisation of pain

    Time frame: 30 minutes after second PBM session for the experimental and control 1 groups and 30 minutes after analgesic treatment for the group control 2 (Day 1)

    Pain will be characterised using the shortened QDSA questionnaire. The control groups will be compared with the MILTA device.

  4. Evaluation of the total quantity of analgesics consumed during the hospital stay

    Time frame: through the hospital stay, an average of 2 or 3 days

    Recording of the type and dose of analgesics consumed.

  5. Evaluation of the improvement of postpartum comfort

    Time frame: 30 minutes after first PBM session for the experimental and control 1 groups and 30 minutes after analgesic treatment for the group control 2

    Postpartum confort will be assessed using 5 modalities scale

  6. Evaluation of the improvement of postpartum comfort

    Time frame: 30 minutes after second PBM session for the experimental and control 1 groups and 30 minutes after analgesic treatment for the group control 2 (Day 1)

    Postpartum confort will be assessed using 5 modalities scale

  7. Evaluation of the involvement of caregivers during the hospital stay

    Time frame: through the hospital stay, an average of 2 or 3 days

    Recording the number of calls to the healthcare team related to pain

  8. Safety evaluation

    Time frame: through study completion, an average of 10 days

    Adverse event record

Sponsors and collaborators

Lead sponsor

Elsan

Other

Registry information

Official study title

Evaluation of the Efficacy of the Photobiomodulation on the Pelvi-perineal Pain in Patients in Immediate Post-partum Situation

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
May 21, 2021
Registry last updated
Feb 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.